In Non-Redundant, the frequency of IDH1 mutation was 100% in lower-grade glioma, and cancer types with IDH2 mutation >10% included acute myeloid leukemia, myelodysplastic syndromes, and primary central nervous system lymphoma (Figure S1A,B). This evidence concerns the gene IDH1 and cancer.